Ionis Pharmaceuticals Inc

19.10.2026 г., 20:02 ч. UTC

Ionis Pharmaceuticals gains following a positive opinion from the CHMP recommending an extension of TRYNGOLZA®'s indication for treating severe hypertriglyceridemia.

16.10.2026 г., 20:07 ч. UTC

Ionis Pharmaceuticals received a positive CHMP opinion for TRYNGOLZA, aimed at treating severe hypertriglyceridemia, despite shares declining amid ongoing market weakness.

15.10.2026 г., 20:02 ч. UTC

UBS upgraded Ionis Pharmaceuticals to Buy from Neutral and raised its price target to $88 from $46, contributing to advancing shares.

14.10.2026 г., 20:07 ч. UTC

Ionis Pharmaceuticals Inc shares are modestly higher, aligning with a broader market gain since Tuesday.

12.10.2026 г., 20:03 ч. UTC

Ionis Pharmaceuticals Inc shares fell sharply, declining from Friday's close and remaining well below their 20-day moving average amid a steep session-long drop.

9.10.2026 г., 20:01 ч. UTC

Ionis Pharmaceuticals Inc shares are advancing amid high trading volume, despite a decline in the Michigan Consumer Sentiment index to a five-month low of 46.3.

8.10.2026 г., 20:07 ч. UTC

Ionis Pharmaceuticals Inc shares are declining, following broader market trends, after an earlier spike that led to a steady decline during Thursday's session.

7.10.2026 г., 19:46 ч. UTC

Ionis Pharmaceuticals Inc is trading higher, showing a slight uptick since Tuesday's close, despite being significantly down compared to a month ago.

6.10.2026 г., 22:50 ч. UTC

Ionis Pharmaceuticals Inc is declining in after-market trading, showing unusual volatility and trading near the lower end of its one-month range.

5.10.2026 г., 20:06 ч. UTC

Ionis Pharmaceuticals Inc's shares traded roughly flat, maintaining a position near Friday's close amid a broader market with minimal movement.

2.10.2026 г., 20:07 ч. UTC

Ionis Pharmaceuticals Inc shares fell, continuing a three-session decline and remaining significantly below the 20-day moving average amid broader biotechnology sector weakness.

1.10.2026 г., 20:07 ч. UTC

Ionis Pharmaceuticals Inc shares fell sharply, closing at the day's lowest point amid broader market weakness and significant losses over the past month.

30.09.2026 г., 19:51 ч. UTC

Ionis Pharmaceuticals Inc shares fell sharply, reaching their lowest point since Tuesday's close amid significant weakness in the Biotechnology sub-sector.

29.09.2026 г., 20:07 ч. UTC

Ionis Pharmaceuticals Inc is trading modestly higher, having recovered from an earlier pullback, though it remains below its 20-day moving average.

28.09.2026 г., 20:02 ч. UTC

Ionis Pharmaceuticals Inc is advancing with high volume, rebounding sharply in early afternoon trading after earlier pulling back from a session high.

25.09.2026 г., 22:20 ч. UTC

Ionis Pharmaceuticals Inc is trading modestly higher in after-market hours, reflecting broader market gains amid mixed economic signals and rising Treasury yields.

24.09.2026 г., 23:51 ч. UTC

Ionis Pharmaceuticals Inc has advanced in after-market trading, recovering from an initial dip and reaching its highest point of the day.

23.09.2026 г., 23:05 ч. UTC

Ionis Pharmaceuticals Inc reported positive interim results from its Phase 3 IMAgINATION study, leading to a modest after-market hours increase in its stock.

22.09.2026 г., 20:02 ч. UTC

Ionis Pharmaceuticals shares are advancing after positive Phase 3 FUSION study results for ulefnersen, showing significant improvement in functional impairment and survival for FUS-ALS.

21.09.2026 г., 20:06 ч. UTC

Ionis Pharmaceuticals shares are advancing amid posts on social platforms on sales figures for TRYNGOLZA, despite earlier pulling back from a session high.

18.09.2026 г., 20:02 ч. UTC

Ionis Pharmaceuticals Inc shares fell sharply, trading near the lower end of their one-month range amid broader market weakness and high trading volume.

17.09.2026 г., 20:01 ч. UTC

Ionis Pharmaceuticals shares are higher in Thursday's session, showing unusual market volume, despite reports of its drug pelacarsen failing in a clinical trial.

16.09.2026 г., 20:08 ч. UTC

Ionis Pharmaceuticals shares fell amid challenges from its failed Phase 3 ATTR partnership, erasing about $4.63 billion in market value.

15.09.2026 г., 23:01 ч. UTC

Ionis Pharmaceuticals shares are trading higher in after-market hours, despite a broader market decline indicated by a sharp drop in the Empire State Manufacturing Index.

14.09.2026 г., 23:16 ч. UTC

Ionis Pharmaceuticals Inc. shares are higher in after-market trading, though still below the 20-day moving average after six consecutive sessions of declines.

11.09.2026 г., 23:56 ч. UTC

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

10.09.2026 г., 19:16 ч. UTC

Ionis Pharmaceuticals shares are lower as HC Wainwright cuts the price target from $115.00 to $100.00 while maintaining a "buy" rating.

9.09.2026 г., 22:51 ч. UTC

Ionis Pharmaceuticals shares are lower in after-market hours. Broader market trends reflect concerns over rising crude oil prices exceeding $100 amid Middle East tensions.

8.09.2026 г., 23:41 ч. UTC

Ionis Pharmaceuticals Inc shares are lower in after-market trading, reversing earlier gains and reflecting overall weakness without any specific news to explain the decline.

5.09.2026 г., 00:05 ч. UTC

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.